NCT04205435View on ClinicalTrials.gov

β-globin Restored Autologous HSC in β-thalassemia Major Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

July 25, 2022

Conditions
β-thalassemia Major
Interventions
BIOLOGICAL

β-globin restored autologous HSC

gene edited autologous hematopoietic stem cells with β-globin restoration

Trial Locations (1)

200241

Shanghai Bioraylaboratory Inc, Shanghai

Sponsors
All Listed Sponsors
collaborator

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT04205435 - β-globin Restored Autologous HSC in β-thalassemia Major Patients | Biotech Hunter | Biotech Hunter